A Montpellier, southern France company, Sensorion, which specializes in the treatment of pathologies of the inner ear such as hearing loss, tinnitus, and acute vertigo has presented the results of its SENS-218 preclinical trial at the Association for Research in Otolaryngology (ARO) Mid-Winter Meeting held in San Diego, California.
Don't Miss: iPhone 8: Everything You Need to Know
The first pharmacological data had initially been presented at the Neuroscience 2015 annual meeting under the title of “Effective protection against severe noise-induced hearing loss by a small molecule clinical drug candidate following daily, post-trauma systemic administration”.
The preclinical trial was carried out in animals with acute bilateral sensorineural hearing loss, where animals were exposed to about 120 dB noise level for 2 hours and then randomized for 14 days with a placebo or a Sensorion drug from the SENS-200 program. By day 14, the researchers observed improvements in the group tested with SENS-218 compared to those treated with placebo.
“The level of hearing loss was reduced by an average of 50% with SENS-218, showing a recovery of 33.4 dB versus 16.7 dB with placebo (from the same initial level of hearing loss) and a reduction of the average loss of sensory outer hair cells in the most sensitive regions of the cochlea by around 36% on average,” the authors of the study wrote.
A subsequent pharmacokinetic data was presented at ARO under the title “Effective Protection Against Severe Noise-Induced Hearing Loss by an Inner Ear Penetrating, Small Molecule Clinical Drug Candidate Following Daily, Post-Trauma Systemic Administration.” Dr. Jonas Dyhrfjeld-Johnsen, Sensorion’s Head of Pharmacology made the presentation.
People suffering from hearing loss resulting from acoustic trauma do not have a specific drug or treatment procedure for treating them – yet about 11 million suffer from this ailment globally.
How To: Buy a Pokemon Go Plus
“Acceptance of this study for presentation at the ARO meeting is further validation of the science behind our SENS-200 program,” said Pierre Attali, Sensorion’s Chief Medical Officer. “These data support the Sensorion approach to treat inner ear disorders by systemic (oral or IV) administration of drug candidate for the benefit of a large patient population that suffers from acute hearing loss. We look forward to advancing the clinical development of SENS-218 currently entering phase 1 and providing our investors and the medical community with updates on our data as we progress.”